Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Receptor Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective, orally active beta-adrenergic receptor antagonist designed for scientific research only (APExBIO product page). It competitively inhibits beta-adrenergic receptors, reducing heart rate and contractility in cardiovascular models. As a substrate for the organic anion transporting polypeptide 1A2 (OATP1A2), Nadolol's distribution and pharmacokinetics are influenced by transporter expression and experimental context (Sun et al., 2025). Its solid form (C17H27NO4, 309.40 g/mol) is stably stored at -20°C, with prompt use of solutions recommended for maximal efficacy. Nadolol is not approved for diagnostic or medical use, but remains a preferred tool in hypertension, angina, and vascular headache research (see review).

Biological Rationale

Beta-adrenergic receptors mediate sympathetic nervous system effects on cardiovascular tissues. Their overactivation is implicated in hypertension, angina pectoris, and certain vascular headache syndromes. Inhibiting these receptors reduces myocardial oxygen demand, heart rate, and arterial pressure. Non-selective beta-blockers like Nadolol are essential for dissecting beta-adrenergic signaling pathways in translational models (detailed analysis). OATP1A2, a hepatic and extrahepatic transporter, modulates tissue distribution of Nadolol, impacting pharmacokinetics and experimental outcomes (Sun et al., 2025).

Mechanism of Action of Nadolol (SQ-11725)

Nadolol (SQ-11725) acts as a competitive antagonist at both beta-1 and beta-2 adrenergic receptors. This prevents endogenous catecholamines (e.g., norepinephrine, epinephrine) from binding and activating these receptors. The result is decreased cAMP production, reduced calcium influx, and diminished cardiac contractility and rate. These effects translate to lower blood pressure and heart rate in cardiovascular disease models. Because Nadolol is an OATP1A2 substrate, its tissue uptake and elimination depend on transporter activity, which can be influenced by disease state or co-administered compounds (Sun et al., 2025).

Evidence & Benchmarks

• Nadolol demonstrates competitive beta-1 and beta-2 adrenergic blockade, reducing heart rate and myocardial contractility in vivo (site review).
• It is a well-validated OATP1A2 substrate, with transporter expression influencing plasma and tissue levels in animal models (Sun et al., 2025).
• Nadolol's physicochemical properties (solid; MW 309.40 g/mol; C17H27NO4) enable stable storage at -20°C for months; solutions should be used promptly (APExBIO).
• It is widely used in hypertension and angina pectoris research, providing reproducible reductions in systolic blood pressure and heart rate in mammalian models (benchmark analysis).
• Transporter expression changes (e.g., OATP1A2, P-gp, Cyp450s) may cause pharmacokinetic variability, impacting Nadolol's distribution and efficacy in disease models (Sun et al., 2025).

This article updates previous reviews by integrating recent pharmacokinetic variability data (Sun et al., 2025), clarifying transporter-mediated considerations for translational research.

Applications, Limits & Misconceptions

Nadolol is primarily used in research settings to model:

• Hypertension and related vascular disorders
• Angina pectoris and myocardial ischemia
• Vascular headache mechanisms
• Beta-adrenergic signaling pathway modulation

Its predictable pharmacodynamic profile and stable storage conditions make Nadolol suitable for longitudinal and cross-sectional studies. As a non-selective blocker, it provides insight into both beta-1 and beta-2 adrenergic receptor functions.

Common Pitfalls or Misconceptions

• Nadolol is not selective for beta-1 receptors: Use in studies requiring selective blockade may confound data.
• It is not approved for human therapeutic use in research settings: Nadolol (SQ-11725) is for scientific research only—not for clinical or diagnostic application (APExBIO).
• Storage in solution is not recommended long-term: Prepare fresh solutions for each experiment to ensure efficacy.
• Transporter modulation can alter pharmacokinetics: Models with altered OATP1A2 or P-gp expression may require dose adjustments (Sun et al., 2025).
• Not suitable for studies requiring CNS penetration: Nadolol's limited blood-brain barrier permeation restricts its use in central nervous system models.

This article extends prior summaries (see strategic review) by emphasizing workflow-specific parameters and identifying key limitations in transporter-deficient or CNS-targeted studies.

Workflow Integration & Parameters

Nadolol is supplied as a solid compound (C17H27NO4) by APExBIO (SKU: BA5097). Store at -20°C. For solution preparations, dissolve in appropriate buffer or vehicle prior to use. Avoid repeated freeze-thaw cycles. Do not store solutions for extended periods; use promptly to prevent degradation (Nadolol product page).

Shipping is performed with Blue Ice for small molecules. For modified nucleotides, Dry Ice is used. Confirm local regulations for beta-blocker handling. For experimental design, consider OATP1A2 expression in chosen models, as transporter-mediated uptake may affect dose-response relationships (Sun et al., 2025).

For extended guidance on integrating Nadolol into cardiovascular disease models, see this mechanistic insight article, which discusses transporter and pathway cross-talk in greater detail. This article clarifies the practical storage, preparation, and workflow steps for maximizing experimental rigor with Nadolol (SQ-11725).

Conclusion & Outlook

Nadolol (SQ-11725) is a robust, non-selective beta-adrenergic receptor blocker with a well-characterized pharmacological and physicochemical profile. As an OATP1A2 substrate, its pharmacokinetics are predictable yet sensitive to transporter variation, underscoring the need for careful experimental design. APExBIO provides Nadolol (BA5097) as a research-only reagent, supporting its strategic use in cardiovascular disease modeling. Future directions include leveraging transporter biology to refine dosing and expanding application in next-generation hypertension and angina pectoris studies. For comprehensive specifications and ordering, refer to the Nadolol (SQ-11725) product page.